Document is current
Any future updates will be listed below
-
Authors
Boland, Patrick M.
Mukherjee, Sarbajit
Imanirad, Iman
Vijayvergia, Namrata http://orcid.org/0000-0001-6469-4759
Cohen, Seth D.
Gupta, Medhavi
Iyer, Renuka V.
Bakin, Andrei
Wang, Jianxin http://orcid.org/0000-0002-0998-4996
Chatley, Sarah
Cahill, Beth http://orcid.org/0009-0005-8340-7950
Vadehra, Deepak
Attwood, Kristopher
Hochster, Howard S.
Fountzilas, Christos http://orcid.org/0000-0003-3837-5644
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA282430, P30CA016056)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
National Comprehensive Cancer Network
- License Information
-
More Information
Article History
Received: 4 May 2024
Revised: 17 August 2024
Accepted: 28 August 2024
First Online: 7 September 2024
Competing interests
: Dr. Christos Fountzilas has research support for this clinical trial from the National Comprehensive Cancer Network Oncology Research Program (paid to the institute). He has research support from the National Comprehensive Cancer Network Foundation, Taiho Oncology, Pfizer Inc, and Merck Sharp & Dohme Corp (paid to the institute) unrelated to this study. Dr. Sarbajit Mukherjee has received research funding from Ipsen Biopharmaceuticals (paid to the institute) unrelated to this study. Dr. Iman Imanirad has received advisory board compensation from Eisai Co, Ltd, unrelated to this study.
: The study was conducted according to the Declaration of Helsinki principles and approved by the Institutional Review Boards (IRB) from all participating institutions (Roswell Park Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, Moffitt Cancer Center, and Fox Chase Comprehensive Cancer Center). All patients provided informed consent prior to study participation. All patients providing tumor samples for whole transcriptome sequencing (de-identified Roswell Park IRB-approved protocols BDR 155422 and BDR 151721) had provided universal informed consent for use of tumor samples in research.
